Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0006 4971 "

Sökning: L773:0006 4971

Sortera/gruppera träfflistan
  • Abolhassani, H, et al. (författare)
  • Current genetic landscape in common variable immune deficiency
  • 2020
  • Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 135:9, s. 656-667
  • Tidskriftsartikel (refereegranskat)abstract
    • Using whole-exome sequencing to examine the genetic causes of immune deficiency in 235 common variable immunodeficiency (CVID) patients seen in the United States (Mount Sinai, New York), 128 patients from Sweden, and 208 from Iran revealed 68 known disease-causing genes underlying this heterogeneous immune defect. The patients at the time of study ranged from 4 to 90 years of age. Overall, 31%, 36%, and 54% of the patients in the US, Swedish, or Iranian cohorts had mutations. The multiplicity of genes identified in the 571 subjects reflects the complex requirements of B-cell antigen signaling, activation, survival, migration, maturation, and maintenance of antibody-secreting memory B-cell populations to the plasma cell stage. For the US and Swedish cohorts, CVID subjects with noninfectious complications, lymphoid infiltrations, inflamatory conditions, or autoimmunity were somewhat more likely to have an identifiable gene, but in both cohorts, numerous subjects with these medical conditions had no potential gene that could be assigned. Specific clinical patterns of illnesses were also not linked to any given gene defect as there was considerable overlap in clinical presentations. These observations led to a new perspective on the complexity of the immunologic phenotype found in CVID syndrome.
  • Abonia, J Pablo, et al. (författare)
  • Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung
  • 2006
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 108:5, s. 1588-1594
  • Tidskriftsartikel (refereegranskat)abstract
    • Normal mouse lungs lack appreciable numbers of mast cells (MCs) or MC progenitors (MCp's), yet the appearance of mature MCs in the tracheobronchial epithelial surface is a characteristic of allergic, T-cell-dependent pulmonary inflammation. We hypothesized that pulmonary inflammation would recruit MCp's to inflamed lungs and that this recruitment would be regulated by distinct adhesion pathways. Ovalbumin-sensitized and challenged mice had a greater than 28-fold increase in the number of MCp's in the lungs. In mice lacking endothelial vascular cell adhesion molecule 1 (VCAM-1) and in wild-type mice administered blocking monoclonal antibody (mAb) to VCAM-1 but not to mucosal addressin CAM-1 (MadCAM-1), recruitment of MCp's to the inflamed lung was reduced by greater than 75%. Analysis of the integrin receptors for VCAM-1 showed that in beta7 integrin-deficient mice, recruitment was reduced 73% relative to wild-type controls, and in either BALB/c or C57BL/6 mice, mAb blocking of alpha4, beta1, or beta7 integrins inhibited the recruitment of MCp's to the inflamed lung. Thus, VCAM-1 interactions with both alpha4beta1 and alpha4beta7 integrins are essential for the recruitment and expansion of the MCp populations in the lung during antigen-induced pulmonary inflammation. Furthermore, the MCp is currently unique among inflammatory cells in its partial dependence on alpha4beta7 integrins for lung recruitment.
  • Abrahamsson, Anna, et al. (författare)
  • Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
  • 2014
  • Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 124:8, s. 1288-1295
  • Tidskriftsartikel (refereegranskat)abstract
    • There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000-2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (HR 1.36; p=0.002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3 year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3 year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n=766; HR 0.66; p=0.001) and autologous stem cell transplant (ASCT) (n=273; HR 0.55; p=0.004) were independently associated with improved overall survival in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice.
  • Abramson, JS, et al. (författare)
  • Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
  • 2023
  • Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 141:14, s. 1675-1684
  • Tidskriftsartikel (refereegranskat)abstract
    • This global, phase 3 study compared lisocabtagene maraleucel (liso-cel) with standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT) were randomized 1:1 to liso-cel (100×106 CAR+ T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS) by independent review. A total of 184 patients were randomized. In this primary analysis with a median follow-up of 17.5 months, median EFS was not reached (NR) for liso-cel versus 2.4 months for SOC (hazard ratio [HR] = 0.356; 95% confidence interval [CI]: 0.243‒0.522). Complete response (CR) rate was 74% for liso-cel versus 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel versus 6.2 months for SOC (HR = 0.400; 95% CI: 0.261‒0.615; P < .0001). Median overall survival was NR for liso-cel versus 29.9 months for SOC (HR = 0.724; 95% CI: 0.443‒1.183; P = .0987). When adjusted for crossover from SOC to liso-cel, median overall survival was NR for liso-cel and SOC (HR = 0.415; 95% CI: 0.251‒0.686). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4/5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel over SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. (ClinicalTrials.gov; NCT03575351.)
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (1043)
konferensbidrag (765)
forskningsöversikt (17)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (941)
övrigt vetenskapligt (885)
aut (174)
Bjorkholm, M (82)
Osterborg, A (81)
Hellstrom-Lindberg, ... (79)
Ringden, O (78)
Rosenquist, Richard (56)
visa fler...
Ljungman, P (49)
Landgren, O (49)
Kimby, E (47)
Gahrton, G (45)
Mellstedt, H (41)
Juliusson, Gunnar (41)
Stamatopoulos, Kosta ... (39)
Kristinsson, SY (35)
Nahi, H (32)
Jacobsen, Sten Eirik ... (28)
Remberger, M. (28)
Ghia, Paolo (28)
Malcovati, L (28)
Niederwieser, D (27)
Paul, C (26)
Karlsson, Stefan (26)
Höglund, Martin (25)
Hassan, M (24)
Samuelsson, J (24)
Abrahamsson, Jonas, ... (24)
Anagnostopoulos, Ach ... (24)
Pospisilova, Sarka (24)
Hast, R (24)
Sutton, Lesley-Ann (23)
Turesson, Ingemar (23)
Lundin, J (23)
Merup, M. (22)
Grander, D (22)
Ehinger, Mats (22)
Lehmann, S (21)
Sundström, Christer (21)
Hasle, Henrik (21)
Sander, B (21)
Jerkeman, Mats (20)
Juliusson, G (20)
Palmblad, J (20)
GRUBER, A (20)
Cazzola, M (20)
Forestier, Erik (19)
Einhorn, S (19)
Dahlbäck, Björn (19)
Simonsson, Bengt (19)
Larsson, Jonas (19)
Porkka, Kimmo (19)
visa färre...
Karolinska Institutet (1287)
Lunds universitet (305)
Uppsala universitet (240)
Göteborgs universitet (73)
Umeå universitet (73)
Linköpings universitet (63)
visa fler...
Kungliga Tekniska Högskolan (15)
Stockholms universitet (7)
Örebro universitet (6)
Högskolan i Halmstad (4)
Chalmers tekniska högskola (3)
Sveriges Lantbruksuniversitet (3)
Luleå tekniska universitet (2)
visa färre...
Engelska (1826)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (545)
Naturvetenskap (16)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy